Clinical and biomarker analyses of first-line nivolumab and relatlimab (nivo-rela) in advanced or resectable melanoma (mel).

Authors: Lilit Karapetyan, Kimberly Ward, Shaliz Aflatooni, Denise Kalos, Carlos Moran-Segura, Bethany Withycombe, Pei-Ling Chen, Kenneth Yee Tsai, Jane Messina, Matthew Perez, Amod Sarnaik, Jonathan S. Zager, Rogerio Izar Neves, Vernon K. Sondak, Keiran Smalley, Joseph Markowitz, Andrew Scott Brohl, Zeynep Eroglu, Ahmad A. Tarhini, Nikhil I. Khushalani

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.9535

Source: Full article


Abstract

9535